Agios Pharmaceuticals (AGIO) saw its shares plummet by 26.8% this week following Novo Nordisk’s (NVO) announcement of promising Phase 3 trial results for its sickle cell disease treatment, etavopivat. This drug demonstrated superiority over Agios’ mitapivat, achieving key endpoints related to hemoglobin response and reducing vaso-occlusive crises, while mitapivat failed to meet its secondary endpoint regarding pain crises.

The implications for Agios are significant, as the competitive landscape for oral pyruvate kinase activators has shifted dramatically. With Novo’s results casting doubt on the market potential for mitapivat, Agios is under pressure to align with the FDA on a trial necessary for accelerated approval. Investors may be particularly concerned about the viability of mitapivat, especially given the recent data.

Looking ahead, Agios has another potential asset in tebapivat, expected to report results in late 2026. This could provide a lifeline for the company if it can demonstrate efficacy in the same market space.

Source: fool.com